This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morahan, P S Articles by Munson, A E Search for Related Content PubMed PubMed Citation Articles by Morahan, P S Articles by Munson, A E

Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus.

ABSTRACT

Previous investigations from our laboratories have demonstrated that cannabinoids possess immunosuppressive properties. The present studies were designed to determine whether these agents decrease host resistance to infections with Listeria monocytogenes and herpes simplex virus type 2. Host resistance was measured by changes in the 50% lethal dose of the pathogen in cannabinoid-treated and control mice. The effect of cannabinoids on resistance to L. monocytogens was dose dependent. Delta-9-tetrhydrocannabinol at doses of 38, 75, and 150 mg/kg suppressed resistance to infection by 10-, 17-, and 657-fold, respectively. Marijuana extract was less active but significantly reduced resistance to L. moncytogenes at all tested doses. Resistance to systemic herpes simplex virus type 2 infection was decreased 96-fold by delta-9-tetrahydrocannabinol, although marijuana extract was inactive. The doses and regimen of treatment with cannabinoids that produced significant decreases in host resistance were similar to those which caused suppression of delayed-type hypersensitivity to sheep erythrocytes. The possible mechanisms and public health aspects of the decreased host resistance produced by marijuana extract and its cannabinoids are discussed.

This article has been cited by other articles:

• Buchweitz, J. P., Karmaus, P. W. F., Williams, K. J., Harkema, J. R., Kaminski, N. E. (2008). Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of {Delta}9-tetrahydrocannabinol. J. Leukoc. Biol. 83: 785-796 [Abstract] [Full Text]  
• Buchweitz, J. P., Karmaus, P. W. F., Harkema, J. R., Williams, K. J., Kaminski, N. E. (2007). Modulation of Airway Responses to Influenza A/PR/8/34 by {Delta}9-Tetrahydrocannabinol in C57BL/6 Mice. J. Pharmacol. Exp. Ther. 323: 675-683 [Abstract] [Full Text]  
• Pacher, P., Batkai, S., Kunos, G. (2006). The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol. Rev. 58: 389-462 [Abstract] [Full Text]  
• Sipe, J. C., Arbour, N., Gerber, A., Beutler, E. (2005). Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J. Leukoc. Biol. 78: 231-238 [Abstract] [Full Text]  
• McKallip, R. J., Nagarkatti, M., Nagarkatti, P. S. (2005). {Delta}-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response. J. Immunol. 174: 3281-3289 [Abstract] [Full Text]  
• Friedman, H., Newton, C., Klein, T. W. (2003). Microbial Infections, Immunomodulation, and Drugs of Abuse. Clin. Microbiol. Rev. 16: 209-219 [Abstract] [Full Text]  
• McKallip, R. J., Lombard, C., Martin, B. R., Nagarkatti, M., Nagarkatti, P. S. (2002). Delta 9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo. J. Pharmacol. Exp. Ther. 302: 451-465 [Abstract] [Full Text]